Regulatory pathways for novel peptide‑drug conjugates under updated FDA CMC guidance

What are the key elements of the updated FDA CMC guidance for peptide‑drug conjugates?

The draft guidance released in September 2023 outlines a structured CMC framework for peptide‑drug products, including peptide‑drug conjugates (PDCs) Clinical Pharmacology Considerations for Peptide‑Drug Products – FDA. The core elements are:

1. Product definition and classification – PDCs are treated as complex biologics when the peptide component exceeds 50 % of the molecular weight, otherwise as small‑molecule drugs with biologic attributes.
2. Manufacturing process description – Detailed flow diagrams, critical process parameters, and control strategies for both peptide synthesis and conjugation chemistry must be provided.
3. Analytical characterisation – Identity, purity, potency, and impurity profiling using orthogonal techniques (e.g., LC‑MS, NMR, HPLC, SDS‑PAGE) are required. The guidance stresses the need for method validation in accordance with ICH Q2(R1).
4. Stability testing – Real‑time and accelerated stability data covering the drug substance, drug product and the conjugate linkage are mandatory, with recommended testing intervals of 0, 3, 6, 12 and 24 months for the first two years.
5. Pharmacology and toxicology considerations – Immunogenicity assessment, off‑target binding and linker‑cleavage studies should be integrated into the CMC package.
6. Regulatory submission content – The guidance specifies the sections to be included in IND, NDA or BLA submissions, aligning with ICH M4(R2) and FDA’s eCTD format.

These elements replace the fragmented approach previously applied to peptide‑based therapeutics and provide a single reference point for sponsors developing novel PDCs.

How does the FDA classify novel peptide‑drug conjugates for regulatory submission?

The guidance distinguishes three regulatory categories based on molecular size, mechanism of action and manufacturing complexity:

| Category | Typical molecular weight | Primary regulatory pathway | |----------|--------------------------|----------------------------| | Small‑molecule peptide‑drug conjugates | < 1 kDa peptide component | IND → NDA (under 505(b)(1)) | | Complex peptide‑drug conjugates | 1–5 kDa peptide component, defined linker | IND → NDA or BLA (if biologic‑like) | | Large‑molecule peptide‑drug conjugates | > 5 kDa peptide component, often with protein carrier | IND → BLA (Biologics License Application) |

The classification determines whether the sponsor files an NDA or a BLA, which in turn dictates the review division (CDER vs. CBER). For PDCs that fall near the boundary, the FDA recommends a pre‑submission meeting to confirm the appropriate pathway.

What data packages are required for CMC of peptide‑drug conjugates under the new guidance?

The guidance enumerates a minimum data set for each submission stage:

• Identity – Mass spectrometry (HR‑MS), peptide mapping, and sequence verification.
• Purity and related substances – Quantification of residual solvents, protecting‑group remnants, and linker‑derived impurities using validated HPLC‑UV/FLR methods.
• Potency – Bioassays that reflect the conjugate’s mechanism (e.g., cell‑based cytotoxicity for ADC‑type PDCs) together with a physicochemical surrogate assay.
• Stability – Forced‑degradation studies to demonstrate linker integrity under pH 2–8, temperature 25–40 °C, and oxidative stress.
• Manufacturing controls – In‑process controls for peptide coupling efficiency, conjugation stoichiometry, and final drug‑product fill‑weight consistency.
• Container‑closure – Compatibility studies with primary packaging (glass vials, pre‑filled syringes) to assess leachables and extractables.
• Reference standards – Certified reference material (CRM) for assay calibration, with a documented traceability chain.

All data must be presented in the eCTD format, with cross‑referencing to the IND‑safety package where applicable. The guidance also encourages the inclusion of a Control Strategy narrative that links critical quality attributes (CQAs) to process parameters, supporting a risk‑based approach consistent with ICH Q8(R2).

How do the updated guidance requirements impact timelines and post‑approval obligations?

While the guidance does not prescribe fixed timelines, it outlines expectations that can affect development schedules:

• Pre‑IND meetings – Early engagement is advised to resolve classification and data‑package scope, potentially reducing downstream review cycles.
• IND preparation – The expanded CMC section adds roughly 30–45 pages of documentation compared with legacy peptide INDs, which may extend the compilation phase by 2–3 months.
• Review time – FDA’s target review time for NDAs remains 10 months (standard) or 6 months (priority). For BLAs, the target is 12 months. The guidance states that a well‑structured CMC dossier can facilitate a “no‑major‑issue” review, avoiding additional information requests.
• Post‑approval changes – Any modification to the peptide synthesis route, linker chemistry or conjugation process is considered a major change and requires a Prior Approval Supplement (PAS) under 21 CFR 314.70. The guidance provides a decision‑tree to help sponsors assess the regulatory impact of such changes.
• Lifecycle management – The FDA encourages the use of comparability studies when implementing process improvements, with a focus on maintaining CQAs and clinical performance.

Overall, the updated guidance aims to bring greater predictability to the regulatory pathway for PDCs, but sponsors should allocate additional resources for CMC documentation and early FDA interaction.

Frequently asked questions

Q1: Are peptide‑drug conjugates always considered biologics? A: Not necessarily. Classification depends on the peptide’s proportion of the molecular weight and the complexity of the conjugate. Small‑molecule PDCs follow the drug‑product pathway (IND/NDA), whereas larger, protein‑based conjugates are reviewed as biologics (IND/BLA).

Q2: Do I need a separate IND for the peptide component and the conjugate? A: No. The guidance recommends a single IND that integrates the CMC, pharmacology and toxicology data for the complete conjugate, with the peptide component described as part of the overall drug substance.

Q3: How should I address linker stability in the CMC dossier? A: Provide forced‑degradation data demonstrating linker integrity under relevant pH, temperature and oxidative conditions, and include real‑time stability results for the final drug product.

Q4: What is the preferred format for analytical method validation? A: Validation should follow ICH Q2(R1) guidelines, covering specificity, accuracy, precision, linearity, range and robustness. Include a summary table in the eCTD with method parameters and acceptance criteria.

Sources

• Clinical Pharmacology Considerations for Peptide‑Drug Products – FDA
• Clinical Pharmacology Considerations for Peptide‑Drug Products – HHS
• Clinical Pharmacology Considerations for Peptide‑Drug Products – Draft Guidance for Industry (Federal Register, 11 Sept 2023)